SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Amendment No. 1)
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
September 20, 2022
Date of Report (Date of earliest event reported)
Enveric Biosciences, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
4851 Tamiami Trail N, Suite 200
Naples, FL 34103
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: (239) 302-1707
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Common stock, par value $0.01 per share||ENVB||The Nasdaq Stock Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 4.01 Changes in Registrant’s Certifying Accountant.
This Current Report on Form 8-K/A is being filed solely to amend the Current Report on Form 8-K filed by Enveric Biosciences, Inc. (the “Company”) on September 23, 2022 (the “Original Report”) to add as Exhibit 16.1 the letter received on October 6, 2022 from the Company’s former independent registered public accounting firm, Friedman LLP, regarding the disclosure made in the Original Report.
Item 9.01 Financial Statements and Exhibits.
|16.1||Letter of Friedman LLP to the Securities and Exchange Commission, dated October 6, 2022.|
|104||Cover Page Interactive Data File (formatted as Inline XBRL).|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: October 6, 2022||ENVERIC BIOSCIENCES, INC.|
|By:||/s/ Joseph Tucker|
|Chief Executive Officer|
October 6, 2022
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re: Enveric Biosciences, Inc.
Commission File Number 001-38286
We have read the statements made by Enveric Biosciences, Inc. under Item 4.01 of its Form 8-K dated September 23, 2022, as amended by the Current Report Form 8-K/A Amendment No.1 on October 6, 2022 and we agree with the statements concerning our firm; we are not in a position to agree or disagree with other statements Enveric Biosciences, Inc. contained therein.
Very truly yours,
/s/ Friedman LLP
East Hanover, New Jersey